Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor
Weidong Liu
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorCorresponding Author
Hideji Nakamura
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorTohru Tsujimura
Department of Pathology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, and
Search for more papers by this authorJidong Cheng
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorTeruhisa Yamamoto
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorYuna Iwamoto
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorHiroyasu Imanishi
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorSoji Shimomura
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorTetsuo Yamamoto
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorTsutomu Hirasawa
Discovery Research Laboratories, Shionogi Company, Sagisu 5-12-4, Fukushima-ku, Osaka City, Osaka 533-0002, Japan
Search for more papers by this authorShuichiro Inagaki
Discovery Research Laboratories, Shionogi Company, Sagisu 5-12-4, Fukushima-ku, Osaka City, Osaka 533-0002, Japan
Search for more papers by this authorShuhei Nishiguchi
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorToshikazu Hada
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorWeidong Liu
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorCorresponding Author
Hideji Nakamura
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorTohru Tsujimura
Department of Pathology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, and
Search for more papers by this authorJidong Cheng
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorTeruhisa Yamamoto
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorYuna Iwamoto
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorHiroyasu Imanishi
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorSoji Shimomura
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorTetsuo Yamamoto
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorTsutomu Hirasawa
Discovery Research Laboratories, Shionogi Company, Sagisu 5-12-4, Fukushima-ku, Osaka City, Osaka 533-0002, Japan
Search for more papers by this authorShuichiro Inagaki
Discovery Research Laboratories, Shionogi Company, Sagisu 5-12-4, Fukushima-ku, Osaka City, Osaka 533-0002, Japan
Search for more papers by this authorShuhei Nishiguchi
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorToshikazu Hada
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501,
Search for more papers by this authorAbstract
Cyclooxygenase 2 (COX-2) and retinoid X receptor α (RXRα) are suggested to have roles in carcinogenesis. COX-2 inhibitors have been reported to suppress growth of hepatocellular carcinoma (HCC) cell lines in vitro. However, little is known about the preventive effect of these drugs on spontaneous hepatocarcinogenesis in vivo. Etodolac exists in a racemic mixture containing S- and R-etodolac. S-etodolac is responsible for COX-2 inhibitory activity and R-etodolac is related to the downregulation of RXRα. Here, the effect of etodolac on spontaneous development of HCC in fatty liver Shionogi mice is evaluated. Etodolac was administered at a low (2 mg/kg) or high (10 mg/kg) dose three times a week for 16 months starting at the age of 3 months. The development of HCC was suppressed slightly in the high-dose group, and suppressed markedly in the low-dose group, although the development of fatty liver was not inhibited in either group. Plasma prostaglandin E2 levels were also decreased significantly in the low-dose group, consistent with the suppression of HCC. The expression of RXRα and proliferating cell nuclear antigen in non-tumorous liver tissues was decreased significantly in both the low-dose and high-dose groups. These findings show that etodolac treatment at an optimum dose suppresses hepatocarcinogenesis in vivo, and may be useful for preventing the development of HCC in humans. (Cancer Sci 2006; 97: 768–773)
References
- 1 Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13: S169–71.
- 2 El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–50.
- 3 Takai K, Okuno M, Yasuda I et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 2005; 48: 39–45.
- 4 Habu D, Shiomi S, Tamori A et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358–61.
- 5 Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–5.
- 6 Kern MA, Schoneweiss MM, Sahi D et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004; 25: 1193–9.
- 7 Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891–9.
- 8 Peek RM Jr. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother Pharmacol 2004; 54 (Suppl. 1): 850–6.
- 9 Gupta S, Adhami VM, Subbarayan M et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 3334–43.
- 10 Futakuchi M, Ogawa K, Sano M, Tamano S, Takeshita F, Shirai T. Suppression of lung metastasis by aspirin but not indomethacin in an in vivo model of chemically induced hepatocellular carcinoma. Jpn J Cancer Res 2002; 93: 1175–81.
- 11 Denda A, Endoh T, Kitayama W et al. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, 1-amino acid-defined diet in rats. Carcinogenesis 1997; 18: 1921–30.
- 12 Denda A, Kitayama W, Murata A et al. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, l-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis 2002; 23: 245–56.
- 13 Marquez-Rosado L, Trejo-Solis MC, Garcia-Cuellar CM, Villa-Trevino S. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 2005; 43: 653–60.
- 14 Cheng J, Imanishi H, Liu W et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 2004; 95: 666–73.
- 15 Demerson CA, Humber LG, Abraham NA, Schilling G, Martel RR, Pace-Asciak C. Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 1983; 26: 1778–80.
- 16 Becker-Scharfenkamp U, Blaschke G. Evaluation of the stereoselective metabolism of the chiral analgesic drug etodolac by high-performance liquid chromatography. J Chromatogr 1993; 621: 199–207.
- 17 Kolluri SK, Corr M, James SY et al. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci USA 2005; 102: 2525–30.
- 18 Huan B, Siddiqui A. Retinoid X receptor RXR alpha binds to and trans-activates the hepatitis B virus enhancer. Proc Natl Acad Sci USA 1992; 89: 9059–63.
- 19 Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J General Virol 1997; 78: 1527–31.
- 20 Tsutsumi T, Suzuki T, Shimoike T et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937–46.
- 21 Soga M, Kishimoto Y, Kawaguchi J et al. The FLS mouse: a new inbred strain with spontaneous fatty liver. Lab Anim Sci 1999; 49: 269–75.
- 22 Soga M, Kishimoto Y, Kawamura Y, Inagaki S, Makino S, Saibara T. Spontaneous development of hepatocellular carcinomas in the FLS mice with hereditary fatty liver. Cancer Lett 2003; 196: 43–8.
- 23 Japanese Association for Laboratory Animal Science. Guidelines for animal experimentation. Exp Anim 1987; 36: 285–8.
- 24 Frith CH, Ward JM. A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol Toxicol 1979; 3: 329–51.
- 25 Cheng J, Imanishi H, Ijima H et al. Expression of cyclooxygenase 2 and cytosolic phospholipase A2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res 2002; 23: 185–95.
- 26 Nishizawa H, Morita M, Sugimoto M, Imanishi S, Manabe N. Effects of in utero exposure to bisphenol A on mRNA expression of arylhydrocarbon and retinoid receptors in murine embryos. J Reprod Dev 2005; 51: 315–24.
- 27 Friedl R, Brunner M, Moeslinger T, Spieckermann PG. Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages. Life Sci 2000; 68: 417–29.
- 28 Koga H, Sakisaka S, Ohishi M et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999; 29: 688–96.
- 29 Sung YK, Hwang SY, Kim JO, Bae HI, Kim JC, Kim MK. The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells 2004; 17: 35–8.
- 30 Mayoral R, Fernandez-Martinez A, Bosca L, Martin-Sanz P. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 2005; 26: 753–61.
- 31 Kishimoto Y, Takata N, Jinnai T et al. Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 2000; 47: 812–19.
- 32 Yoshimi N, Kawabata K, Hara A, Matsunaga K, Yamada Y, Mori H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 1997; 88: 1044–51.
- 33 Yoshimi N, Shimizu M, Matsunaga K et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl) methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999; 90: 406–12.
- 34 Cheng J, Imanishi H, Amuro Y, Hada T. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 2002; 99: 755–61.
- 35 Waris G, Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 2005; 79: 9725–34.
- 36 Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 2002; 110: 1831–8.
- 37 Cheng AS, Chan HL, To KF et al. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 2004; 24: 853–60.
- 38 Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003; 24: 1353–9.
